Puma Biotechnology, Inc.PBYINASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank82
3Y CAGR-37.2%
5Y CAGR+9.8%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
-37.2%/yr
Quarterly compound
5Y CAGR
+9.8%/yr
Recent deceleration
Percentile
P82
Within normal range
vs 5Y Ago
1.6x
Solid growth
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 5.58% |
| Q3 2025 | 2.98% |
| Q2 2025 | 11.46% |
| Q1 2025 | -8.61% |
| Q4 2024 | 20.90% |
| Q3 2024 | -7.96% |
| Q2 2024 | 0.33% |
| Q1 2024 | 5.55% |
| Q4 2023 | 12.47% |
| Q3 2023 | -14.31% |
| Q2 2023 | 5.12% |
| Q1 2023 | -7.82% |
| Q4 2022 | 22.49% |
| Q3 2022 | -5.96% |
| Q2 2022 | -21.47% |
| Q1 2022 | 7.55% |
| Q4 2021 | -24.78% |
| Q3 2021 | 1.06% |
| Q2 2021 | -7.86% |
| Q1 2021 | -16.27% |
| Q4 2020 | 3.50% |
| Q3 2020 | -5.46% |
| Q2 2020 | -3.00% |
| Q1 2020 | -15.83% |
| Q4 2019 | 0.80% |
| Q3 2019 | -18.60% |
| Q2 2019 | 3.24% |
| Q1 2019 | -7.03% |
| Q4 2018 | 5.49% |
| Q3 2018 | -15.83% |
| Q2 2018 | -7.84% |
| Q1 2018 | -6.52% |
| Q4 2017 | 1.41% |
| Q3 2017 | -7.04% |
| Q2 2017 | -2.82% |
| Q1 2017 | -2.84% |
| Q4 2016 | 8.51% |
| Q3 2016 | -4.13% |
| Q2 2016 | -9.95% |
| Q1 2016 | 14.68% |